Arcus Biosciences, Inc.
PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS
Last updated:
Abstract:
Methods of identifying compounds that modulate the conversion of AMP to adenosine by 5'-nucleotidase, ecto, and that possess particular pharmacokinetic characteristics are described herein. Methods of such compounds, and compositions comprising same, for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, are also provided.
Status:
Application
Type:
Utility
Filling date:
8 Mar 2019
Issue date:
31 Dec 2020